The UK and US have signed a significant trade agreement that will guarantee zero tariffs on UK medicine exports being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has committed to boost expenditure on drugs through the NHS. This move guarantees that duties on these crucial goods will remain at zero for a timeframe of the next three years.
This deal is in response to recent statements to significantly raise tariffs on branded drug imports, with figures floated up to double the cost.
"This deal with the UK reinforces the international landscape for new treatments and establishes much-needed balance to transatlantic pharmaceutical trade," a release noted.
Economic Significance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the US, which is easily the primary destination for major companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period to the end of September, the UK exported medicines valued at £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This deal safeguards jobs, increases capital expenditure and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact entails several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates were more than 20%.
Industry Background
This agreement follows a ongoing dispute between the sector and the UK government over spending levels and NHS adoption.
The disagreement were exacerbated by assertions that American customers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been directed toward American operations.
One official stated that the NHS must spend more on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
